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Criteria for selection of ESRD treatment modalities. The most strategy may be based, also, on clinical status, patient
important renal replacement therapies (RRT) for end-stage age, patient preference, psychological stability, etiology
renal disease (ESRD) patients are hemodialysis (HD), perito- of ESRD, comorbidity, suitable living-related donor,neal dialysis (PD) and renal transplantation (RT). Survival,
economic factors and social circumstances.morbidity and quality of life are the main factors to select
the best RRT modality for a particular patient. The outcome
comparison suggest that RT is a better overall treatment for
DIALYSIS VS. RENAL TRANSPLANTESRD patients. On the other hand, the studies that compared
patient outcome for HD and PD have yielded conflicting re- Patient survival after RT is markedly better than that
sults. Neither treatment modality is best suited for all patients. seen with either HD or PD [1–4]. However, some of theThe choice should be analyzed for each particular patient con-
benefits associated with transplantation are related tosidering his demographic and comorbid conditions. Diabetic
patient selection, since dialysis patients with the mostpatients, patients with cardiovascular disease and elderly pa-
tients are high risk populations and they are discussed indepen- serious comorbid conditions are not accepted for the
dently. The frequency of treatment modalities in the different transplant waiting list and hence remain in the dialysis
countries is not in accordance with the analysis of the advan-
group. Some comparative studies of dialysis vs. RT sur-tages and disadvantages of each one. Non-medical reasons
vival have considered that the transplant group is favoredare important factors in dialysis modality selection. In our
experience the expertise of the nephrologic team is the most by inclusion of these high-risk patients in the dialysis
important one. RT, HD and PD should not be seen as compet- group [2, 3, 5, 6].
ing therapeutic options, rather, they are complementary meth- We analyzed survival for ESRD patients on dialysisods of dealing with uremia. An integrated approach combining
vs. after transplantation, adjusting for the variables thatHD, PD and RT is necessary to devise an individualized treat-
were significantly and independently related with mortal-ment program permitting optimal long-term physical and psy-
chological well being and adequate integration in the family ity [7]. This analysis concluded that, when the outcome
and society. is adjusted to comorbid factors, there are no differences
between RT recipients’ and HD patients’ survival in non-
diabetic patients, while RT gives better survival than HD
Technological and immunological developments within in diabetics patients. Overall survival was significantly
the last two decades have evolved several renal replace- higher in RT recipients than in HD patients (P , 0.0001).
ment therapy (RRT) options. The most important of However, treatment modality did not show a significant
them in the treatment of end-stage renal disease (ESRD) relation with mortality when analyzed together with age,
patients are hemodialysis (HD), peritoneal dialysis (PD) heart disease, cancer and smoking habit. In non-diabetic
and renal transplantation (RT). patients, survival adjusted for age, heart disease, cancer
Each modality has advantages and disadvantages. The and smoking habit was similar in RT recipients and HD
challenge for the nephrologist is to devise an individual- patients (RR 5 1.03, P 5 0.87). On the contrary, when
ized treatment program permitting optimal long-term
only diabetic patients were considered, treatment modal-
physical and psychological well being and adequate inte-
ity was significantly and independently related to mortal-gration in the family and society. These goals are most
ity. Five-year adjusted survival was 89.2% for RT recipi-effectively achieved by an integrated approach combin-
ents and 40.9% for HD patients (P 5 0.017). Relative risking HD, PD and RT.
is not the same over time, that is, it is not proportional.Survival, morbidity and quality of life are the most
HD patients had better initial survival in the first yearimportant factors to select the best RRT modality for a
and the RT recipients had higher long-term survival [7].particular patient. The rational long-term management
We suggest that ESRD patients without comorbid risk
factors at the start of dialysis provide an ideal population
Key words: hemodialysis, peritoneal dialysis, renal transplant. for survival comparisons among different centers or dif-
ferent treatment modalities [8]. When only this low risk 2000 by the International Society of Nephrology
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group was used to compare survival, no differences were Survival and quality of life comparisons suggest that
RT is a better overall treatment for ESRD patients. Theobserved. Ten-year survival was 87.9% for HD patients
(N 5 134) and 82.6% for RT recipients (N 5 289) (P 5 benefits may be greater for diabetic patients than for
non-diabetic patients, and this fact might be considered0.231) [7].
Our data agree with several studies [2, 3, 5, 6]. Vollmer in cadaveric kidney allocation. However, we believe that
the choice of treatment modality should be analyzed foret al [2] and Hutchinson et al [5] found a similar survival
with dialysis and cadaveric transplantation, after control- each particular patient considering his demographic and
comorbid conditions.ling for pretreatment risk factors. Garcia-Garcia et al [6]
found a markedly lower mortality risk among diabetic
transplant recipients than diabetic dialysis patients, al-
HEMODIALYSIS VS. PERITONEAL DIALYSIS
though their findings did not achieve statistical sig-
Many studies that compared patient survival for HDnificance. Port et al [3] compared mortality risk among
patients and patients on either CAPD or continuouscadaveric RT recipients vs. transplant candidates on dial-
cyclic peritoneal dialysis (CCPD) have yielded conflict-ysis in the cyclosporine era. They used a time-dependent
ing results (Table 1). The majority of the studies suggestCox analysis to eliminate the time-to-treatment bias.
that patient survival is comparable with these two modal-Their dialysis group had been limited to those patients
ities [12–15]. Fenton et al [16] compared mortality rateswho were accepted to the transplant waiting list, in order
between HD and CAPD/CCPD patients using Poissonto reduce the bias related to patient selection. They ob-
regression modeling for incident patients and controllingserved a markedly lower long-term risk (RR 0.25) among
for age, primary renal diagnosis and predialysis comorbiddiabetic RT recipients compared with diabetic wait-listed
conditions. The mortality rate ratio for CAPD/CCPDdialysis patients (P , 0.001) and no differences among
relative to HD was 0.73 (95% CI; range 0.67–0.78). Twopatients with glomerulonephritis or hypertension as cause
studies that analyzed data from the United States Renalof ESRD.
Data Systems (USRDS), using Poisson regression mod-These data suggest that the survival differences ob-
eling and adjusting for demographic characteristics re-served with dialysis or RT in non-diabetic patients sur-
ported increased risk on PD relative to HD or no differ-vival are not due to the relative efficacy of the treatments.
ence between both treatment. Bloembergen et al [17]The pretreatment clinical status of the patients would
compared mortality in prevalent patients and they re-be the major factor determining the different outcomes.
ported increased adjusted mortality risk on PD relativeWhile, in diabetic patients, the different outcomes might
to HD. Vonesh and Moran [18] found little or no differ-be attributed to a higher benefit of RT.
ence between PD and HD, including both prevalent andQuality of life is only beginning to be used in depth
incident populations (Table 1).as an outcome measure, and much work is needed to
To date, no randomized controlled trial of PD vs. HDstandardize research methodology and thus move this
therapy has been conducted. Conclusions resulting fromarea forward. Transplant recipients displayed a higher
different observational studies are contradictory due toquality of life based on subjective measures such as life
the differences of the study population, sample size orsatisfaction and general well being. Successful cadaveric
available data on comorbid conditions. Study designtransplants were associated with a marked and significant
must also be considered in the interpretation of results.improvement in psychosocial well being (P , 0.002) even
The information offered by incident patient studies usingthough physical activity did not increase [9]. Life satisfac-
an intention-to-treat analysis that assigns patients to thetion was higher in transplanted patients than in dialysis
initial modality and does not consider changes in dialyticpatients; dialysis patients were more anxious (P , 0.05)
modality is ideal for advising new patients. A prevalentand more depressed (P , 0.001) than transplanted pa-
patient study should be interpreted for patients alreadytients [10]. It has been reported that patients with func-
on ESRD therapy and not for advising new ESRD pa-tioning transplants were more likely to be able to work
tients [19].(nearly 75%) than dialysis patients (25% to 59%) [11].
Morbidity comparisons between HD patients andHowever, other studies suggested that RT recipients are
CAPD patients have also yielded contradictory data.economically not more productive than patients on dial-
Some studies do not show differences in the averageysis [10].
days of hospitalization and others find that the time ofThese and other studies concluded that there is objec-
hospitalization is higher in CAPD than in HD [13, 20].tive evidence of successful rehabilitation and better qual-
Maiorca et al [21] found higher hospitalization time inity of life for RT recipients in comparison to HD and
CAPD patients (20.0 days per patient year) than patientscontinuous ambulatory peritoneal dialysis (CAPD) pa-
on bicarbonate HD (12.4 days per patient year). Thetients. However, further comparisons are needed, con-
cause of higher hospitalization in CAPD patients wassidering that RT recipients have a better functional state
at the outset. related to peritonitis episodes. After the Y system was
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Table 1. Hemodialysis versus peritoneal dialysis: Risk of death in each dialysis modality
Study HD CAPD/CCPD P or (95% CI)
Wolfe RA et al 1990 1.0 0.98 NS
Serkes KD et al 1990: Non-diabetics 1.0 0.62 NS
Maiorca R et al 1991 1.0 1.34 NS
Held PJ et al 1994: Non-diabetics 1.0 0.84 NS
Bloembergen WE et al 1995:
USRDS 1987–1989 1.0 1.19 0.001
Fenton SSA et al 1997:
CORR 1990–1994 1.0 0.73 (0.67–0.78)
Vonesh EF, Moran J, 1999:
USRDS 1987–1989 1.0 1.17 0.001
USRDS 1989–1991 1.0 1.06 NS
USRDS 1990–1992 1.0 1.06 NS
USRDS 1991–1993 1.0 1.08 0.043
Table 2. Renal transplantation contraindicationsintroduced, the frequency of peritonitis has decreased.
We can expect that technical improvements will allow Advanced age (.70-year-old)
Malignancy (unless free of recurrence for several years)prevention of this complication and minimize the differ-
Severe chronic pulmonary diseaseences. Cardiac failure resistant to treatment
Data from quality of life comparisons between HD Severe peripheral vascular disease
Severe neuropathy with trophic ulcerand CAPD are controversial. Some studies suggest that
Advanced liver diseaseCAPD patients have an improved quality of life and Active infection
superior psychosocial adaptation to their condition com- Active vasculitis
Active glomerulonephritispared to in-center HD patients [22]. Other studies found
Uncorrectable lower urinary tract problemsthat overall quality of life was almost equal between
patients on HD and patients on PD [23].
In the absence of a randomized trial comparing PD
with HD, more extensive studies including adjustment
justing for age and comorbidity, showed that diabeticfor disease severity, dose of dialysis, and nutritional sta-
patients had 2.39 greater risk of death than non-diabetictus are needed to better ascertain if differences in out-
patients (P , 0.0001) [9]. On the other hand, survivalcome between patients treated with PD vs. HD truly
after RT is, at present, similar in diabetic and non-dia-exist [18].
betic patients [1, 26]. In the Uruguayan Registry at De-
cember 1997, 10-year survival after transplant was 74%
DEMOGRAPHIC AND COMORBID FACTORS for diabetic patients and 79% for non-diabetic patients,
respectively.Demographic and comorbid conditions should be con-
In diabetic patients RT is the best choice. Howeversidered in choosing treatment modality. Diabetes, car-
the patients should be selected considering the risk afterdiovascular disease and older age are the most important
transplantation. The most significant predictors of mor-factor of death risk in ESRD patients. Diabetic patients,
tality are preexisting ischemic heart disease, stroke andpatients who have cardiovascular disease, and elderly
peripheral vascular disease. Khauli et al [4] observedpatients present particular characteristics and will be an-
significantly lower survival among patients with ischemicalyzed independently. Younger ages and absence of com-
heart disease before transplantation. One- and five-yearorbidity are conditions that are best treated by early
survival was 76% and 19% for patients with and 94%transplantation. Children should receive renal trans-
and 40% for patients without this condition (P 5 0.0002).plantation as soon as feasible. For patients with auto-
Adjusted survival showed no difference between type Inomic neuropathy who have frequent episodes of hypo-
and type II diabetic patients after RT. Differences ob-tension during HD sessions, CAPD/CCPD should be the
served are due to the different frequency of cardiovascu-preferred dialysis treatment. In our opinion, there are
lar complications [27]. Type II diabetic patients whoseveral clinical conditions where transplantation is con-
received a renal allograft had a higher survival rate com-traindicated (Table 2).
pared with patients maintained on HD treatment [27].
DIABETIC PATIENTS Renal transplantation should be considered as the treat-
ment of choice in diabetic patients without vascular com-Mortality of patients on dialysis is higher in diabetic
plications.than in non-diabetic patients [1, 24, 25]. In our experi-
ence, the survival analysis of 531 patients on HD, ad- Clinical vascular evaluation and the study of arterio-
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Table 3. Risk of death on hemodialysis versus peritonealsclerotic heart disease are mandatory before transplant
dialysis for diabetic patients
[27]. Diabetic transplant candidates older than 35 years
HD CAPD/CCPD P or (95% CI)of age or with clinical evidence of arterial disease should
Held PJ et al 1994:undergo an extensive vascular assessment, including
USRDS 1.0 1.26 0.03stress thallium myocardial imaging. Coronary arteriogra-
Marcelli D et al 1995:
phy should be carried out if clinical symptoms or study Lombardy Registry NS
Bloembergen WE et al 1995:alterations are present. As discussed below, coronary
USRDS 1987–1989 1.0 1.38 ,0.001revascularization should be strongly considered before
Fenton SSA et al 1997:
RT in patients with coronary artery disease. It has been CORR 1990–1994 (age ,65) 1.0 0.73 (0.62–0.87)
CORR 1990–1994 (age $65) 1.0 0.88 (0.73–1.06)reported that patients with significant coronary disease
Vonesh EF, Moran J, 1999:have a trend to better survival after RT than when main-
USRDS 1989–1991 1.0 1.10 ,0.001
tained on dialysis [4] and that coronary revascularization USRDS 1990–1992 1.0 1.18 ,0.001
USRDS 1991–1993 1.0 1.18 ,0.001significantly decreases the number of cardiac events after
RT [28]. Cardiac failure resistant to treatment; severe
peripheral vascular disease and severe neuropathy are
considered definitive contraindications for RT [29].
Combined pancreas-kidney transplantation (PKT) diabetic patients. Bloembergen et al [17] reported for
and particularly simultaneous pancreas and kidney trans- prevalent patients an increased death rate on PD relative
plantation performed from a single cadaveric donor, has to HD. Data from the Canadian Registry (CORR)
become an important option in selected insulin-depen- showed better results in PD than HD. Fenton et al [16],
dent diabetic patients because of its ability to offer supe- controlling for comorbid conditions, reported a de-
rior glycemic control and improved quality of life with creased mortality rate ratio for CAPD/CCPD relative
greater potential for rehabilitation. Neither patient mor- to HD for incident patients younger than 65 years old.
tality nor kidney graft survival is significantly altered by Data from the Lombardy Registry, after taking into ac-
adding a pancreas to kidney transplantation [30, 31]. count the main comorbid conditions, showed no differ-
However, overall morbidity after the combined opera- ences between the treatments [32].
tion is greater than that after kidney transplantation Diabetic patients show high mortality and poor quality
alone. Greater morbidity in PKT patients included car- of life, not only when they require dialysis treatment,
diovascular, sepsis and noninfectious urologic complica- but also in the predialysis phase. A high proportion of
tions [31]. In addition to greater morbidity, a high mortal- diabetic patients with renal failure dies before initiation
ity was observed associated with PKT in some reports of dialysis and cardiovascular disease is the most fre-
[30]. For these reasons, most transplant centers have quent cause of death [33]. Prevention of cardiovascular
restricted PKT to young patients with few diabetic com- disease is the most important factor to increase diabetic
plications and no coronary artery disease [30]. patient survival. We believe that therapy, before dialysis,
Although RT is the preferred treatment for diabetic on dialysis and after kidney transplantation should be
ESRD patients, most patients are placed on dialysis ei- individualized to the patient’s specific medical circum-
ther while awaiting RT or as their only therapy. The stances. Attention to control of hypertension, obesity
question of which dialysis modality provides the best and hyperlipidemia may slow the course of macrovascu-
outcome remains unresolved. It had been noted that lar disease, particularly of the coronary arteries, which
CAPD has several advantages. CAPD avoids vascular threatens long-term survival of ESRD diabetic patients.
access problems. It also improves blood pressure control
and volume extraction is slower and better tolerated.
PATIENTS WITH CARDIOVASCULAR DISEASECAPD allows greater independence and offers the op-
Cardiovascular disease is common in patients on long-portunity to treat many diabetics at home, even those
term dialysis, and it accounts for almost 50% of overallin the high risk population because of age and/or cardio-
mortality in this group [1, 24, 25]. It is a strong predictorvascular instability. CAPD offers excellent control of
of mortality in patients with ESRD [34, 35].blood glucose levels using the intraperitoneal route to
Dialysis management of patients with a prior history ofadminister insulin. Because of these observations, CAPD
congestive heart failure, cardiomegaly, or ischemic hearthad been proposed as the first therapeutic option in
disease is a difficult problem. In HD, the intradialyticESRD diabetic patients. However, PD patient survival
hypotension may be associated with arrhythmias, myo-has not proved to be significantly higher than HD patient
cardial ischemia, mesenteric ischemia and worsening ofsurvival (Table 3). Data from the USRDS suggested
retinopathy [36]. It was reported that type II diabetic pa-better results on HD than on PD. Held et al [15] reported
tients with frequent (2 or more) intradialytic hypotensivethat mortality adjusted for comorbidity was higher in
CAPD than HD, overall and particularly among older episodes (systolic blood pressure lower than 80 mm Hg)
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had 2.8 times greater risk of myocardial infarction death indicated that the life expectancy of ESRD patients aged
[33]. 65 is roughly one-fourth that of a patient of the same
There are several reports of successful PD perfor- age without ESRD [1]. The impact of ESRD on life
mance in subjects with severe heart failure [37, 38]. Toler- expectancy decreases with increasing age, and is smallest
ance of the procedure, fluid management, prevention of for the oldest age groups.
arrhythmias, and patient survival were satisfactory in An acceptable subjective quality of life and degree of
these reports. Advantages of PD in patients with cardio- rehabilitation have been noted in several reports [44, 45].
vascular disease include better hemodynamic control, In contrast, other recent studies painted a much grimmer
less acute hypokalemia (which could result in arrhyth- picture of the life of elderly dialysis patients [46, 47].
mia), and better control of anemia. It has been reported Outcomes observed support the policy that dialysis
that left ventricular mass decreased after six months of should not be denied to elderly patients if there is hope
treatment with CAPD but not with HD, and it has been for prolongation of an enjoyable span of life. However,
suggested that CAPD is more appropriate to improve the dialysis should not be used merely to prolong the dying
cardiac function [39]. CAPD/CCPD or hemofiltration process. There are elderly patients who should not be
should be the selected treatment modality in patients started on dialysis and the major absolute contraindica-
with severe cardiovascular instability. tions to dialysis are advanced malignancy, irreversible
If HD is indicated, bicarbonate dialysate buffer should dementia, advanced liver disease, advanced chronic ob-
be used. Anemia should be corrected with erythropoietin structive pulmonary disease or severe cardiomyopathy.
to achieve an hematocrit of near 35%. Cardiovascular When there is doubt about chances of recovery from a
performance can be enhanced in many HD patients by severe underlying disease, a “trial” of dialysis may be
increasing the dialysate calcium concentration and using offered. Withdrawal of dialysis at a later time is prefera-
cool temperature dialysate, which can also increase vas- ble to withholding it from the beginning.
cular resistance. Sequential ultrafiltration and isovolemic Few specific studies have addressed comparative sur-
dialysis, the use of a higher dialysate sodium concentra- vival between HD and PD in the elderly. Most studies
tion (.140 mEq/L) and intake of caffeine to blunt the indicate that survival of elderly patients on CAPD and
effect of the endogenous vasodilator adenosine may also on HD is similar [22, 43]. Two Italian reports, adjusting
prevent episodic hypotension [40]. for comorbid conditions, showed that mortality was
It is commonly accepted that the evaluation for arterio- higher among older patients treated with HD [14, 48].
sclerotic heart disease is mandatory before RT and the While large studies in the United States have suggested
correction of a coronary lesion should be strongly consid- that the benefit of HD in the elderly is most prominent
ered in patients with coronary artery disease. We believe in diabetic patients [49]. The technique failure is more
that all patients on dialysis, even if they are not transplant frequent when CAPD/CCPD is used. It was reported
candidates, must be evaluated with the same criteria as that the switching at one year in elderly subjects was
non-uremic subjects. The indications for percutaneous 12.5% from CAPD/CCPD to HD and 1.7% from HD
transluminal coronary angioplasty (PTCA) or coronary to CAPD/CCPD [49].
artery bypass grafting (CABG) must take into account Elderly patients have frequent vascular access diffi-
the reported results. CABG is considered the best treat- culties that can contribute to decreased dialysis delivery.
ment because the risk of cardiac events is higher follow-
Many elderly people do not have suitable vessels for
ing PTCA than after CABG [41, 42].
successful creation of an endogenous arteriovenous (AV)
fistula and this is particularly true in patients with diabe-
ELDERLY PATIENTS tes or hypertensive vascular disease. A polytetrafluoro-
ethylene (PTFE) graft is recommended in these patients.Demographic data demonstrate that the dialysis popu-
However, every opportunity for the construction of anlation is growing progressively older. In the United
endogenous AV fistula should be taken. Recent dataStates, the fraction of ESRD incident patients older than
from the USRDS indicate that the risk of access failure65 years reached 46% in 1996 [1]. The most frequent
in patients over age 65 with an AV fistula is 24% lowertreatment modality in elderly ESRD is in-center HD. In
than in similar patients having a PTFE graft [50].the United States, 82% of elderly patients were on HD,
Elderly patients on HD experience more intradialytic10% on CAPD and only 2.7% had a functioning trans-
complications, such as hypotension, nausea, and vom-plant [43].
iting, than do younger patients. The treatment of hypo-Despite complex medical and psychosocial conditions,
tension is often associated with temporary cessation orsurvival, quality of life and rehabilitation are acceptable
early termination of HD therapy. As we considered be-in the elderly dialysis patients [43]. The five-year survival
fore, the association with diabetes and cardiovascularrate for the 65–74 age group was 21% in the United
States and 38% in Japan [1]. Data from the USRDS disease may increase this problems and CAPD/CCPD
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may be a more satisfactory alternative treatment mod- lent candidates for home HD. Several studies have
shown that patients who use home HD have an increasedality than HD.
Renal transplantation is a relatively recent treatment survival and better quality of life when compared to
those who use different dialysis modalities [54, 55].option among the elderly ESRD. Success of transplanta-
tion in geriatric ESRD patients over the last decade is Psychological stability is more necessary when CAPD
or home HD are selected. Having a living-related donordue to improved patient selection as well as the use of
cyclosporine A and lower doses of corticosteroids. One- is a condition to prefer transplantation. CAPD/CCPD
or home HD are preferable in patients who live at longyear patient and graft survival rates of 85% and 75%,
respectively, have been reported [51]. A controlled sur- distance from the HD center or with unavailability of
transportation. In-center HD is often the only dialysisvival comparison of transplantation and dialysis among
elderly patients based on data from the CORR showed, option in single adults with no support system.
after adjusting for other known prognostic factors, that
patients who received a transplant experienced signifi-
NON-MEDICAL FACTORS THAT MODIFY THE
cantly greater survival probability than those who re-
CHOICE OF TREATMENT MODALITIES
mained on dialysis. Five-year survival rates were 81%
The frequency of the different treatment modalitiesand 51% for the transplant and dialysis groups, respec-
in the different countries is not in accordance with thetively (RR 5 0.47, P , 0.0001) [52].
analysis of the advantages and disadvantages of eachAlthough overall results are good, we believe that RT
modality. Renal transplantation offers the best form ofshould not be offered indiscriminately to the elderly.
RRT for patients with ESRD. However, transplant ratesPatients at risk for coronary arterial disease should be
vary worldwide. The transplant rate in United States,identified and candidates for RT should be selected. The
Spain, Norway, Germany and the Czech Republic wasmanagement of transplantation in the elderly requires
greater than 40 new transplant per million populationan understanding of pharmacology, immunology, and
in 1997. On the other hand, in Japan the transplant ratephysiology peculiar to this age group. Since the elderly
was very low. These wide variations of transplant activityhave a degree of immune incompetence, they require
are dependent on cultural, legal and socioeconomic fac-less aggressive immunotherapy.
tors. The economic status of a country could be a factor;
but, even in industrialized nations there are marked dif-
PATIENT PREFERENCE AND ferences. The most important limitation in renal trans-
PSYCHOSOCIAL FACTORS plant programs is the transplantable organ availability.
However, cultural and religious attitudes also influenceSeveral patient factors may modify the choice of RRT
modality. The most important are patient preference, the choice of transplant as an option.
Related to the choice of dialysis modality, and ac-psychological stability, availability of a living-related do-
nor, social circumstances and economic factors. cording to the previous medical analysis, most patients
can be treated with either HD or CAPD/CCPD. How-Patient participation plays a vital role in the outcome.
The different options for RRT should be discussed with ever, in practice, most patients in the world are treated
with HD; more than 80% of the dialysis population. Iteach patient and the patient preference should be consid-
ered. However, little is known about the reasons for is also interesting to note the differences in the choice
of dialysis modality from country to country. CAPD/chronic dialysis patients to choose to be listed or not
listed for renal transplantation. Recently, these reasons CCPD is very frequent in the UK, Australia, New
Zealand, Canada and Mexico. The percentage of CAPD/have been investigated [53]. The most reported reason
for electing transplantation was “hoping for a better CCPD patients is very low in the rest of the world.
Therefore, nonmedical reasons are the most importantquality of life” (86% of respondents). The reason “hop-
ing it will make me live longer” was reported by 69% factors in dialysis modality selection. According to Nis-
senson et al [56], several nonmedical factors are criticalnever-transplanted patients and by 25% patients with
previous transplant. In never-transplanted patients, the in the relative use of various ESRD modalities: (a) fi-
nancial/reimbursement (b) lack of training of nephrolo-reasons “doctor thought it would be good for me” and
“family and/or friends thought it would be good for me” gists and nurses as well as poor education of patients
about dialysis options (c) resource availability (d) socialwere 50% and 42%, respectively. Patient preference de-
pends strongly on medical or nonmedical information. mores (e) cultural habits. In the authors’ opinion, the
reimbursement differences of the physician or the facili-Although the patient’s preferences should be taken into
consideration, the nephrologist has the responsibility to ties (for HD or CAPD/CCPD) are critical in the modality
selection.make recommendations.
Motivated patients with available resources, no matter We do not deny the significance of the financial factors,
but in our experience the knowledge and training of thewhat their cause of ESRD, should be considered as excel-
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3. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Compar-nephrologic team (physicians and nurses) is the most
ison of survival probabilities for dialysis patients vs cadaver renal
important factor in the selection. In center HD was de- transplant recipients. JAMA 270:1339–1343, 1993
veloped earlier than CAPD/CCPD in most countries. 4. Khauli RB, Steinmuller DR, Novick AC, Buszta C, Goormastic
M, Nakamoto S, Vidt DG, Magnusson M, Paganini E, SchreiberConversely when CAPD/CCPD became a mature RRT,
MJ: A critical look at survival of diabetics with end-stage renalmany teams had already a good experience and practice disease: Transplantation versus dialysis. Transplantation 41:598–
in HD. In these centers, the first choice may continue 602, 1986
5. Hutchinson TA, Thomas DC, Lemieux JC, Harvey CE: Prognos-to be HD. In those centers with good experience in all
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reasons will be the key factors to select the modality. In 6. Garcia-Garcia G, Deddens JA, D’Achiardi-Rey R, First MR,
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with end-stage renal disease: a multi-variate analysis of risk factorschoice of dialysis modality will be highly influenced by and survival in 341 successive patients. Am J Kidney Dis 5:10–18,
nonmedical and “nonpatient” reasons. Obviously, an 1985
7. Mazzuchi N, Gonza´lez-Martı´nez F, Carbonell E, Curi L, Fer-economic factor is also connected to this RRT history.
na´ndez-Cean J, Orihuela S: Comparison of survival for hemodial-Substantial capital investment was necessary in those
ysis patients vs renal transplant recipients treated in Uruguay.
countries where in center HD was first developed. In Nephrol Dial Transplant, in press
8. Mazzuchi N, Carbonell E, Ferna´ndez-Cean J: ESRD patientsthese centers and from a business perspective, to keep
without co-morbid risk factors at the start of hemodialysis arethe HD facility as full as possible to offset high fixed
ideal as survival comparison population. Nephrol Dial Transplant
costs is a very important objective. This economic factor 14:1091–1096, 1999
9. Rodin G, Voshart K, Cattran D, Halloran P, Cardella C,may slow the patient transfer to CAPD/CCPD and can
Fenton S: Cadaveric renal transplant failure: the short-term se-interfere with the medical decision. The team bias deter-
quelae. Int J Psychiatry Med 15:357–364, 1985–86
mined both by the training deficit and economic factors 10. Waiser J, Budde K, Schreiber M, Peibst O, Koch U, Bohler T,
could be overcome in several ways. Hoffken B, Hauser I, Neumayer HH: The quality of life in end
stage renal disease care. Transplant Int 11(Suppl 1):S42–S45, 1998Centers involved in both dialysis (HD and CAPD/
11. Evans RW, Manninem DL, Garrison LP, Hart LG, Blagg CR,CCPD) and transplantation are the best for an adequate Gutman RA, Hull AR, Lowrie EG: The quality of life of patients
management of ESRD patients. It may be that a unit is with end stage renal disease. N Engl J Med 312:553–559, 1985
12. Wolfe RA, Port FK, Hawthorne VM, Guire KE: A comparisonunable to provide the full range of services. In such a
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